The Global Health Body Sounds Alert Over Acute Lack of Obesity Jabs

Under 10% of individuals that would benefit from obesity jabs like Wegovy can access them, states the WHO as it issues its inaugural recommendations on the medications.

With more than one billion people worldwide now living with obesity, it is advocating for increased and just availability to this class of drugs.

According to projections, over two billion could be obese by 2030 unless action is taken.

"The new guidelines recognises that obesity is a lifelong illness that can be treated with comprehensive and lifelong care," remarked its chief Tedros Adhanom Ghebreyesus.

High costs, constrained manufacturing, and distribution challenges are significant hurdles to universal access to the treatments that can assist patients in reducing substantial body mass, notes the organization.

GLP-1 Therapy Shortage

Despite the present best projected case, the manufacturing of these medications could only cover approximately 100 million people – fewer than 10% of eligible patients, as stated by the WHO.

The advice calls on governments and firms to expand access, via strategies such as voluntary licensing.

Exclusive production rights on semaglutide – the main component of Novo Nordisk's Wegovy – is set to lapse in several countries in 2026.

The Way Obesity Jabs Operate

GLP-1 drugs replicate a biological compound to reduce digestion speed, curb appetite and boost the sense of being full so people reduce food intake.

Individuals commonly start to lose weight in the initial weeks of commencing the weekly injections.

Studies points to patients may put most of the weight back on a year later of stopping the medication, as their usual food cravings return.

To be overweight or obese raises your risk for developing diseases, including diabetes, heart disease, brain attack, and specific cancers.

Obesity impacts individuals in all nations and was linked to 3.7 million fatalities worldwide in 2024, as per the WHO.